Seasonal influenza vaccine uptake among patients with cardiovascular disease in Denmark, 2017-2019.
Cardiovascular
Influenza
Registry
Vaccine
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
07 08 2023
07 08 2023
Historique:
received:
04
05
2022
revised:
12
07
2022
accepted:
08
08
2022
medline:
8
8
2023
pubmed:
12
8
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Influenza vaccination protects against morbidity and mortality in patients with cardiovascular disease (CVD). We aimed to describe influenza vaccine uptake in patients with CVD in a universal-access healthcare system. Using nationwide Danish registries, we included all patients with prevalent CVD, defined as heart failure (HF), atrial fibrillation (AF), ischemic heart disease (IHD), or stroke during three consecutive influenza seasons (October-December 2017-2019). The outcome was relative frequency of influenza vaccination across strata of patient characteristics. There was an average of 397 346 patients with CVD yearly during 2017-2019. Vaccine uptake was 45.6% for the whole population and ranged from 55.0% in AF to 61.8% in HF among patients aged ≥65 years. Among patients aged <65 years, uptake was 32.6% in HF, 19.0% in AF, 21.1% in IHD, and 18.3% in stroke. There was a lower uptake with decreasing age: 21.6% in HF, 5.5% in AF, 7.4% in IHD, and 6.3% in stroke among males aged <45 years, as opposed to 25.5% in HF, 11.5% in AF, 13.8% in IHD, and 12.1% in stroke for males aged 45-54 years. In the further stratified analyses, uptake ranged from a low of 2.5% for males <45 years with AF who were not vaccinated the previous season to a high of 87.0% for females ≥75 years with IHD who were vaccinated the previous season. Seasonal influenza vaccine uptake is suboptimal among patients with CVD, even in a universal-access healthcare system with free-of-charge vaccinations. Vaccine uptake was particularly low among young patients.
Sections du résumé
BACKGROUND
Influenza vaccination protects against morbidity and mortality in patients with cardiovascular disease (CVD). We aimed to describe influenza vaccine uptake in patients with CVD in a universal-access healthcare system.
METHODS
Using nationwide Danish registries, we included all patients with prevalent CVD, defined as heart failure (HF), atrial fibrillation (AF), ischemic heart disease (IHD), or stroke during three consecutive influenza seasons (October-December 2017-2019). The outcome was relative frequency of influenza vaccination across strata of patient characteristics.
RESULTS
There was an average of 397 346 patients with CVD yearly during 2017-2019. Vaccine uptake was 45.6% for the whole population and ranged from 55.0% in AF to 61.8% in HF among patients aged ≥65 years. Among patients aged <65 years, uptake was 32.6% in HF, 19.0% in AF, 21.1% in IHD, and 18.3% in stroke. There was a lower uptake with decreasing age: 21.6% in HF, 5.5% in AF, 7.4% in IHD, and 6.3% in stroke among males aged <45 years, as opposed to 25.5% in HF, 11.5% in AF, 13.8% in IHD, and 12.1% in stroke for males aged 45-54 years. In the further stratified analyses, uptake ranged from a low of 2.5% for males <45 years with AF who were not vaccinated the previous season to a high of 87.0% for females ≥75 years with IHD who were vaccinated the previous season.
CONCLUSION
Seasonal influenza vaccine uptake is suboptimal among patients with CVD, even in a universal-access healthcare system with free-of-charge vaccinations. Vaccine uptake was particularly low among young patients.
Identifiants
pubmed: 35953403
pii: 6661416
doi: 10.1093/ehjqcco/qcac049
pmc: PMC10405130
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
474-481Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Am Heart J. 2022 Feb;244:50-53
pubmed: 34599883
Vaccine. 2017 Apr 25;35(18):2396-2403
pubmed: 28343782
Circulation. 2011 Nov 29;124(22):2458-73
pubmed: 22052934
BMC Infect Dis. 2015 Oct 17;15:429
pubmed: 26474974
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
MMWR Recomm Rep. 2020 Aug 21;69(8):1-24
pubmed: 32820746
Medicine (Baltimore). 2020 Jan;99(1):e18540
pubmed: 31895791
Ann Intern Med. 2022 Jan;175(1):1-10
pubmed: 34781717
Scand J Public Health. 2011 Jul;39(7 Suppl):34-7
pubmed: 21775348
Eur Heart J Open. 2021 Aug 02;1(2):oeab015
pubmed: 35919262
Eur Heart J. 2011 Jul;32(14):1730-5
pubmed: 21289042
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
J Am Heart Assoc. 2021 Aug 3;10(15):e019671
pubmed: 34315229
Circulation. 2006 Oct 3;114(14):1549-53
pubmed: 16982936
J Am Heart Assoc. 2021 Mar 16;10(6):e019636
pubmed: 33719496
J Gen Intern Med. 2020 Sep;35(9):2801-2803
pubmed: 32583345
BMJ Open. 2016 Nov 18;6(11):e012832
pubmed: 27864249
JAMA Cardiol. 2021 Jan 1;6(1):87-91
pubmed: 32902562
Ann Intern Med. 2020 Oct 20;173(8):605-613
pubmed: 32833488
JAMA. 2013 Oct 23;310(16):1711-20
pubmed: 24150467
Diabetes Care. 2020 Sep;43(9):2226-2233
pubmed: 32647052
Circulation. 2021 Nov 2;144(18):1476-1484
pubmed: 34459211
J Am Heart Assoc. 2022 Mar 15;11(6):e021715
pubmed: 35132866
JAMA Cardiol. 2016 Jun 1;1(3):274-81
pubmed: 27438105
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Eur Heart J Qual Care Clin Outcomes. 2021 Mar 15;7(2):172-180
pubmed: 33107909
Eur Heart J. 2008 Jun;29(11):1350-8
pubmed: 18187561
Circulation. 2019 Jan 29;139(5):575-586
pubmed: 30586760